The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022.
Pang X, Xu W, Liu Y, Li H, Chen L.
Eur J Med Chem · review-article; review; journal article · DOI 10.1016/j.ejmech.2023.115491 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för px-12. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
12 träffarSynthesis and discovery of Baylis-Hillman adducts as potent and selective thioredoxin reductase inhibitors for cancer treatment.
He YL, Zhong M, Song ZL, Shen YK, Zhao L, Fang J.
Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2023.117169A review of the latest research on M<sup>pro</sup> targeting SARS-COV inhibitors.
Yang H, Yang J.
RSC Med Chem · review-article; review; journal article · DOI 10.1039/d1md00066gThe race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2.
Shagufta, Ahmad I.
Eur J Med Chem · review-article; review; journal article · DOI 10.1016/j.ejmech.2021.113157Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
Amin SA, Banerjee S, Ghosh K, Gayen S, Jha T.
Bioorg Med Chem · research support, non-u.s. gov't; research-article; review; journal article · DOI 10.1016/j.bmc.2020.115860COVID-19 therapy: What weapons do we bring into battle?
de Almeida SMV, Santos Soares JC, Dos Santos KL, Alves JEF, Ribeiro AG, Jacob ÍTT, da Silva Ferreira CJ, Dos Santos JC, de Oliveira JF, de Carvalho Junior LB, de Lima MDCA.
Bioorg Med Chem · research support, non-u.s. gov't; research-article; journal article · DOI 10.1016/j.bmc.2020.115757COVID-19: Drug Targets and Potential Treatments.
Gil C, Ginex T, Maestro I, Nozal V, Barrado-Gil L, Cuesta-Geijo MÁ, Urquiza J, Ramírez D, Alonso C, Campillo NE, Martinez A.
J Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1021/acs.jmedchem.0c00606Fight against novel coronavirus: A perspective of medicinal chemists.
Amin SA, Jha T.
Eur J Med Chem · review-article; review; journal article · DOI 10.1016/j.ejmech.2020.112559Selective inhibition of extracellular thioredoxin by asymmetric disulfides.
DiRaimondo TR, Plugis NM, Jin X, Khosla C.
J Med Chem · research-article; journal article; research support, n.i.h., extramural · DOI 10.1021/jm301775sStudies toward novel peptidomimetic inhibitors of thioredoxin-thioredoxin reductase system.
Kłossowski S, Muchowicz A, Firczuk M, Swiech M, Redzej A, Golab J, Ostaszewski R.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/jm201359dSelective alkylation of beta(II)-tubulin and thioredoxin-1 by structurally related subsets of aryl chloroethylureas leading to either anti-microtubules or redox modulating agents.
Fortin JS, Côté MF, Lacroix J, Desjardins M, Petitclerc E, C-Gaudreault R.
Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2008.06.028Cycloalkyl-substituted aryl chloroethylureas inhibiting cell cycle progression in G0/G1 phase and thioredoxin-1 nuclear translocation.
Fortin JS, Côté MF, Lacroix J, Patenaude A, Petitclerc E, C-Gaudreault R.
Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2008.05.028